These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18661593)

  • 21. New pediatric dosing information for Kaletra.
    AIDS Patient Care STDS; 2008 Jul; 22(7):604. PubMed ID: 18661592
    [No Abstract]   [Full Text] [Related]  

  • 22. New pediatric dosing recommendations for atazanavir.
    AIDS Patient Care STDS; 2008 Apr; 22(4):347. PubMed ID: 18434948
    [No Abstract]   [Full Text] [Related]  

  • 23. Generic stavudine approved.
    AIDS Patient Care STDS; 2009 May; 23(5):396-7. PubMed ID: 19422067
    [No Abstract]   [Full Text] [Related]  

  • 24. Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations.
    de Waal R; Kroon SM; Holgate SL; Horn AR; Tooke LJ; Norman J; Smith P; Blockman M; Cotton MF; McIlleron HM; Cohen K
    Pediatr Infect Dis J; 2014 Dec; 33(12):1231-3. PubMed ID: 24945881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA notifications. FDA approved pediatric efficacy supplement for Retrovir syrup.
    AIDS Alert; 2008 Nov; 23(11):128. PubMed ID: 19043870
    [No Abstract]   [Full Text] [Related]  

  • 26. [Toxic epidermal necrolysis in relation with nevirapine].
    Vera Méndez FJ; Martínez Madrid OJ; García Henarejos JA; García Solano J; Vilaplana García R
    An Med Interna; 2000 Aug; 17(8):448-9. PubMed ID: 11218998
    [No Abstract]   [Full Text] [Related]  

  • 27. HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
    Gatanaga H; Yazaki H; Tanuma J; Honda M; Genka I; Teruya K; Tachikawa N; Kikuchi Y; Oka S
    AIDS; 2007 Jan; 21(2):264-5. PubMed ID: 17197830
    [No Abstract]   [Full Text] [Related]  

  • 28. Is pediatric labeling really necessary?
    Christensen ML; Helms RA; Chesney RW
    Pediatrics; 1999 Sep; 104(3 Pt 2):593-7. PubMed ID: 10469796
    [No Abstract]   [Full Text] [Related]  

  • 29. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
    Martinson NA; Morris L; Johnson J; Gray GE; Pillay V; Ledwaba J; Dhlamini P; Cohen S; Puren A; Steyn J; Heneine W; McIntyre JA
    AIDS; 2009 Apr; 23(7):809-16. PubMed ID: 19287298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity.
    Wooltorton E
    CMAJ; 2004 Mar; 170(7):1091. PubMed ID: 15051689
    [No Abstract]   [Full Text] [Related]  

  • 31. Generic zidovudine oral solution approved.
    AIDS Patient Care STDS; 2008 Jul; 22(7):605. PubMed ID: 18661594
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA notifications. Tentative approval for generic nevirapine tablets.
    AIDS Alert; 2007 Oct; 22(10):118-9. PubMed ID: 18418905
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacy. Update: Black box warnings for FDA-approved antiretrovirals.
    Edmunds-Ogbuokiri T
    HIV Clin; 2006; 18(2):12-3. PubMed ID: 16941775
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA notifications. FDA gives tentative approval for stavudine, lamivudine & nevirapine tablet.
    AIDS Alert; 2009 Sep; 24(9):105-6. PubMed ID: 19938312
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA notifications. FDA changes information for stavudine label.
    AIDS Alert; 2002 May; 17(5):67. PubMed ID: 12030220
    [No Abstract]   [Full Text] [Related]  

  • 38. Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Ramírez-Hernández M; Sánchez-Sierra B; Martínez-Escribano JA
    Acta Derm Venereol; 2007; 87(5):442-3. PubMed ID: 17721659
    [No Abstract]   [Full Text] [Related]  

  • 39. Nevirapine (Viramune): European warning.
    AIDS Treat News; 2000 May; (342):4. PubMed ID: 12870458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Labeling changes for Reyataz.
    AIDS Patient Care STDS; 2008 Sep; 22(9):761. PubMed ID: 18802976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.